Advancing Healthcare Decision-Making Through Network Meta-Analysis

by Clinixir

2 min read

May 30, 2025 2:38:19 PM

Clinixir's HEOR Services: Expert NMA Solutions in Oncology

At Clinixir, we offer sophisticated Network Meta-Analysis (NMA) modeling as a core component of our Health Economics and Outcomes Research (HEOR) services. Our recent internal workshop in Lung Cancer Pharmacological Treatment demonstrates our commitment to delivering high-quality evidence synthesis for healthcare decision-makers.

What Our NMA Expertise Delivers:

Comprehensive Evidence Synthesis

Our advanced NMA methodologies allow for comparing multiple interventions simultaneously, even when they haven't been directly compared in clinical trials.

Personalized Treatment Insights

Our analysts can stratify results by relevant biomarkers and patient characteristics, enabling more precise treatment recommendations.

Robust Statistical Frameworks

We employ cutting-edge statistical techniques to ensure reliable, reproducible, and clinically relevant outcomes.

Case Study: Immunotherapy in Advanced NSCLC

Our recent workshop focused on comparing immunotherapy regimens for first-line treatment of advanced non-small cell lung cancer. The analysis:

Synthesized evidence

from 6 Phase III randomized controlled trials involving over 3,000 patients

Evaluated treatments

across different PD-L1 expression subgroups (<1%, 1-49%, and ≥50%)

Identified optimal combinations

for specific patient populations

Aligned findings

with regulatory approvals and clinical guidelines

Key Insights from Our Analysis:

PD-1 inhibitor combinations with chemotherapy demonstrated significant overall survival benefits compared to chemotherapy alone in the overall patient population

For patients with PD-L1 expression 1-49%, certain immunotherapy-chemotherapy combinations showed particularly strong survival benefits (HR = 0.52-0.61)

For patients with PD-L1 expression ≥50%, a dual immunotherapy approach yielded the most promising results (HR = 0.47)

Stratification by biomarker status revealed critical differences in treatment efficacy, highlighting the importance of personalized treatment selection

Visualizing Our NMA Methodology and Results

Figure 1: Network Map of Available Comparisons: This network map illustrates the connections between treatment regimens in our analysis. Node size represents the number of studies for each regimen, while line width indicates the number of direct comparisons available.

Figure 2: Comparative Efficacy by PD-L1 Expression: These league tables present hazard ratios with 95% credible intervals for overall survival across different PD-L1 expression levels. Values below 1.00 indicate improved survival benefit.

Our NMA Service Process:

Systematic Literature Review

Comprehensive search strategy and rigorous study selection

Statistical Analysis

State-of-the-art NMA modeling with appropriate heterogeneity assessments

Clinical Interpretation

Translation of statistical findings into actionable clinical insights

Publication Support

Expert medical writing for manuscripts, reports, and HTA submissions

Why Choose Clinixir for NMA

Our multidisciplinary team combines expertise in clinical research, biostatistics, and medical writing to deliver insights that support formulary decisions, health technology assessments, and clinical practice guidelines.

" Network Meta-Analysis represents a powerful tool in the HEOR toolkit, allowing stakeholders to make evidence-based decisions even in the absence of head-to-head clinical trials."

#HEOR #NetworkMetaAnalysis #RealWorldEvidence #MarketAccess #EvidenceSynthesis

Request RFP Form